Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease

Metabolic dysfunction-associated fatty liver disease(MAFLD)is a complex,heterogenous and progressive disease that is characterised by substantial phenotypic variability,which results in disparate clinical presentations and outcomes(1-4).Notably,only a proportion of patients with MAFLD progress to the more advanced stages of the disease.Therefore,the identification of the subgroups that have a high risk of disease progression is of paramount importance for clinical care,as well as drug development and clinical trials(5).